We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
T-Cell Responses to Tyrosinase-Derived Self-Peptides in Patients with Leukoderma Induced by Rhododendrol: Implications for Immunotherapy Targeting Melanoma.
- Authors
Takagi, Rie; Kawano, Masaaki; Nakamura, Koichiro; Tsuchida, Tetsuya; Matsushita, Sho
- Abstract
<bold>Background: </bold>Rhododendrol, a phenolic compound contained in lightening/whitening cosmetics, can bind and inhibit tyrosinase and was reported to induce leukoderma in Japan. Only 2% of the cosmetics users are affected, and tacrolimus is effective in treatment of the condition.<bold>Objective: </bold>To test the hypothesis that the disease is an autoimmune disorder.<bold>Methods: </bold>Short-term T-cell lines were established using peripheral blood mononuclear cells from 8 patients with human melanoma-associated and tyrosinase-derived synthetic peptides. The effects of rhododendrol on melanoma immunization were also examined.<bold>Results: </bold>Seven out of 8 patients were positive for HLA-DR4. Both class I- and class II-restricted and tyrosinase peptide-specific T-cell responses were observed. Immunization of mice with rhododendrol-treated and irradiated B16 melanoma cells successfully delayed the growth of melanoma cells in vivo.<bold>Conclusion: </bold>Rhododendrol-induced leukoderma is an autoimmune disorder, with rhododendrol as an environmental factor and HLA-DR4 as a genetic factor. Rhododendrol might be effective in treating melanomas.
- Publication
Dermatology (10188665), 2016, Vol 232, Issue 1, p44
- ISSN
1018-8665
- Publication type
journal article
- DOI
10.1159/000441217